- The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc's ALLO ALLO-715 to treat multiple myeloma.
- In April 2021, ALLO-715 received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
- ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
- Price Action: ALLO shares are down 2.35% at $20.75 during the market session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
